About Artus Biotech
Artus Biotech is a Healthcare company based in San Francisco (United States) founded in 2000, and was acquired by Qiagen in May 2005. PCR-based molecular diagnostics for pathogen detection and genotyping are developed. Artus Biotech offers products and services including QIAcuityDx, QIAwave Kits, Proteinase K, TissueLyser III, and QIAseq xHYB Panels. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Diversified. Its competitors include ArcherDX, Inflammatix and Karius; 3 of its 3 listed competitors have raised funding.
Company details
Artus Biotech was established in 2000 in San Francisco, United States, within the biotechnology sector. Operations centered on the creation of PCR-based molecular diagnostics tools, including real-time PCR kits designed for in vitro applications. These products were applied in pathogen detection, genotyping, and pharmacogenomics, supporting clinical and research needs in diagnostics. The company maintained a focus on reliable, targeted assay development for healthcare and scientific use.
- Headquarters San Francisco, United States
- Stage Acquired
- SectorsHealthcare
- Website artus-biotech.com
- Social LinkedIn
- Acquired by Qiagen (May 2005)
Products & Services of Artus Biotech
Artus Biotech offers a comprehensive portfolio of products and services, including QIAcuityDx, QIAwave Kits, Proteinase K, TissueLyser III, and QIAseq xHYB Panels.
Automated digital PCR system for precise genetic variation detection.
Eco-friendly kits for efficient DNA and RNA extraction processes.
Enzyme for protein digestion in biological sample preparation.
Instrument for lysing samples to enable DNA and RNA analysis.
Targeted NGS panels for viral and bacterial pathogen detection.
Investors in Artus Biotech
Artus Biotech has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Qiagen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Products and reagents for molecular diagnostic assays are supplied. | 1984 | qiagen.com | Hilden, Germany |
Investor details for Artus Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Artus Biotech
2 dated milestones of Artus Biotech across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Artus Biotech is founded.
- Exit Acquired by Qiagen.
Competitors of Artus Biotech
Artus Biotech has 3 listed competitors in our database, 3 of them funded. They include ArcherDX, Inflammatix and Karius.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| kariusdx.com | 2014 | Redwood, United States | $315M | 139 | Developer of a non-invasive pathogen blood test for the detection of infectious diseases |
Detailed competitors of Artus Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Artus Biotech (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Artus Biotech
Artus Biotech was founded in 2000.
Artus Biotech is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Artus Biotech was established in 2000 in San Francisco, United States, within the biotechnology sector. Operations centered on the creation of PCR-based molecular diagnostics tools, including real-time PCR kits designed for in vitro applications. These products were applied in pathogen detection, genotyping, and pharmacogenomics, supporting clinical and research needs in diagnostics. The company maintained a focus on reliable, targeted assay development for healthcare and scientific use.
Artus Biotech's top competitors include Inflammatix, ArcherDX and Karius.
Artus Biotech offers QIAcuityDx, QIAwave Kits, Proteinase K, TissueLyser III, and QIAseq xHYB Panels.
Artus Biotech has 1 investor. Key investors include Qiagen.
Yes. Artus Biotech was acquired by Qiagen in May 2005.